Literature DB >> 10555782

Brain soluble fractions which modulate Na+, K+-ATPase activity likewise modify muscarinic receptor.

G Rodríguez de Lores Arnaiz1, P Schneider, C Peña.   

Abstract

Two brain soluble fractions, named peaks I and II, which respectively stimulate and inhibit neuronal Na+, K+-ATPase activity, have been isolated by gel filtration in Sephadex G-50. Since cholinergic transmission seems related to such enzyme activity, in this study we evaluated the effect of brain peak I, peak II, a more purified fraction II-E and commercial ouabain, on specific binding of the muscarinic antagonist [3H]quinuclidinyl benzilate to membranes from rat cerebellum, hippocampus and cerebral cortex. We found that binding was increased by peak I and decreased by peak II, II-E and ouabain, all effects proving concentration-dependent. Since the changes exerted on the muscarinic receptor followed a pattern similar to the one already described for synaptosomal membrane Na+, K+-ATPase activity, both systems seem to interact at a functional level.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10555782     DOI: 10.1023/a:1022536824190

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  36 in total

Review 1.  Allosteric antagonists of the muscarinic acetylcholine receptor.

Authors:  N H Lee; E E el-Fakahany
Journal:  Biochem Pharmacol       Date:  1991-07-05       Impact factor: 5.858

2.  Reduction in the numbers of muscarinic receptors by an endogenous protein.

Authors:  Y I Fang; M Iijima; M Ogawa; T Suzuki; K Momose
Journal:  Biochem Pharmacol       Date:  1993-08-17       Impact factor: 5.858

3.  Agonist and guanine nucleotide modulation of muscarinic cholinergic receptors in cultured heart cells.

Authors:  J B Galper; T W Smith
Journal:  J Biol Chem       Date:  1980-10-25       Impact factor: 5.157

4.  Orthovanadate induces loss of muscarinic cholinergic binding sites.

Authors:  E Danielsson; A Undén; T Bartfai
Journal:  Biochem Biophys Res Commun       Date:  1983-01-27       Impact factor: 3.575

5.  Facilitation of secretion of catecholamines from rat and guinea-pig adrenal glands in potassium-free medium or after ouabain.

Authors:  A R Wakade
Journal:  J Physiol       Date:  1981       Impact factor: 5.182

Review 6.  Phosphorylation of muscarinic receptors: regulation by G proteins.

Authors:  T Haga; K Haga; K Kameyama; H Nakata
Journal:  Life Sci       Date:  1993       Impact factor: 5.037

7.  [The role of a GTP-binding protein in coupling of a muscarinic cholinergic receptor and Na,K-ATPase in myocardial sarcolemma].

Authors:  V K Turmukhambetova; M P Danilenko; M P Panchenko; V B Ritov; O V Esyrev; V A Tkachuk
Journal:  Biokhimiia       Date:  1992-02

8.  Potentiation of K+-evoked catecholamine release in the cat adrenal gland treated with ouabain.

Authors:  A G Garcia; E Garcia-Lopez; J F Horga; S M Kirpekar; C Montiel; P Sanchez-Garcia
Journal:  Br J Pharmacol       Date:  1981-11       Impact factor: 8.739

9.  An endogenous factor which interacts with synaptosomal membrane Na+, K(+)-ATPase activation by K+.

Authors:  G Rodríguez de Lores Arnaiz
Journal:  Neurochem Res       Date:  1993-06       Impact factor: 3.996

10.  Ionic and metabolic requirements for stimulation of secretion by ouabain in bovine adrenal medullary cells.

Authors:  G Pocock
Journal:  Mol Pharmacol       Date:  1983-05       Impact factor: 4.436

View more
  3 in total

Review 1.  How many endobains are there?

Authors:  G Rodríguez de Lores Arnaiz
Journal:  Neurochem Res       Date:  2000-10       Impact factor: 3.996

2.  Repeated electroconvulsive shock induces changes in high-affinity [3H]-ouabain binding to rat striatal membranes.

Authors:  Magda Bignotto; Marco Antonio Campana Benedito
Journal:  Neurochem Res       Date:  2006-05-09       Impact factor: 3.996

Review 3.  Na+/K+-pump and neurotransmitter membrane receptors.

Authors:  Arkady S Pivovarov; Fernando Calahorro; Robert J Walker
Journal:  Invert Neurosci       Date:  2018-11-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.